Startups
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
Overview
Location
Switzerland, Basel-City, Basel
Employees
11-50
Total raised
$48.73M
Founded date
2014
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Dec 20, 2018 | Funding round | $20.26M | |
| Jan 27, 2017 | Seed round | $8.06M |
Mentions in press and media 47
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 8, 2024 | Bio-Europe: Switzerland's Biotech Showcase in Stockholm | The heart of Europe beats strong in Stockholm this November. Bio-Europe, the continent's premier partnering event for the life sciences, is back for its 30th edition. This year, it promises to be a melting pot of innovation, collaboration, ... |
| Nov 5, 2024 | Bio Europe in Stockholm hosts 33 Swiss companies | Currently in its 30-year-edition, BIO-Europe remains Europe's leading partnering event, for the life sciences ecosystem, providing an exceptional opportunity to explore the latest trends learn and connect with potential partners. The past ... |
| May 31, 2024 | Swiss life science startups headed for San Diego | The BIO International Convention 2024, taking place in San Diego from 3 to 6 June, is the largest global biotechnology event with over 20,000 industry leaders from around the world attending. The target group includes representatives from ... |
| May 6, 2024 | Innosuisse funded 45 Start-up innovation projects | With the Start-up innovation project, Innosuisse directly funds high potential science-based projects initiated by Swiss start-ups, giving them a financial boost to propel their market entry. The innovation projects must be based on applic... |
| Nov 6, 2023 | A decent representation at BIO-Europe | |
| Jul 3, 2023 | Swissnex San Francisco Propel Swiss Health Startups into the US Market | |
| Jun 5, 2023 | A significant number of Swiss biotechs exhibit in Boston | |
| May 23, 2022 | Swiss Biotechs display their innovations at BIO 2022 International Convention | |
| Mar 10, 2022 | Fourteen Swiss startups ready for scaling |
Show more
Reviews 0
FAQ about Cellestia Biotech
When was Cellestia Biotech founded?
Cellestia Biotech was founded in 2014.
How much funding has Cellestia Biotech raised?
Cellestia Biotech has raised $48.73M in total across 3 funding rounds.
What funding rounds has Cellestia Biotech raised?
Parsers VC lists 3 funding rounds of Cellestia Biotech, among them a funding round of $20.26M on Dec 20, 2018 and a seed round of $8.06M on Jan 27, 2017.
What has the press written about Cellestia Biotech?
Parsers VC has collected 47 articles mentioning Cellestia Biotech, among them “Bio-Europe: Switzerland's Biotech Showcase in Stockholm” (Nov 8, 2024) and “Bio Europe in Stockholm hosts 33 Swiss companies” (Nov 5, 2024).
Is Cellestia Biotech still active?
Yes, Cellestia Biotech is active; its latest activity on Parsers VC dates from Apr 14, 2025.